Score Overview
Explore the 2021 public Archive ranking →
Where Pfizer Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- PFE
1996: 35.9% · 2021: 43.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 28.72 | — |
1 Year2025-09-26 | $ 22.20 | 29.35% |
5 Years2021-09-28 | $ 33.03 | -13.06% |
10 Years2016-09-28 | $ 20.47 | 40.28% |
20 Years2006-09-28 | $ 11.22 | 156.06% |
30 Years1996-09-27 | $ 4.38 | 6x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 28.72 | $ 22.20 | $ 33.03 | $ 20.47 | $ 11.22 | $ 4.38 |
| Return | — | 29.35% | -13.06% | 40.28% | 156.06% | 6x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 63.69B | $ 4.33B | $ 11.69B |
| 2025 | $ 62.57B | $ 7.77B | $ 13.59B |
| 2024 | $ 63.62B | $ 8.02B | $ 20.47B |
| 2023 | $ 59.55B | $ 2.13B | $ 12.69B |
| 2022 | $ 100.33B | $ 31.36B | $ 22.73B |
| 2021 | $ 81.28B | $ 22.14B | $ 31.06B |
| 2020 | $ 41.65B | $ 9.15B | $ 12.22B |
| 2019 | $ 41.17B | $ 16.27B | $ 9.83B |
| 2018 | $ 53.64B | $ 11.15B | $ 18.83B |
| 2017 | $ 52.54B | $ 21.30B | $ 19.99B |
| 2016 | $ 52.82B | $ 7.21B | $ 17.85B |
| 2015 | $ 48.85B | $ 6.96B | $ 23.29B |
| 2014 | $ 49.60B | $ 9.08B | $ 36.12B |
| 2013 | $ 51.58B | $ 11.64B | $ 32.40B |
| 2012 | $ 54.65B | $ 9.78B | $ 32.39B |
| 2011 | $ 61.03B | $ 8.70B | $ 26.45B |
| 2010 | $ 67.05B | $ 8.26B | $ 28.01B |
| 2009 | $ 50.00B | $ 8.63B | $ 25.96B |
| 2008 | $ 48.29B | $ 8.02B | $ 23.73B |
| 2007 | $ 48.42B | $ 8.21B | $ 25.47B |
| 2006 | $ 48.37B | $ 11.02B | $ 27.71B |
| 2005 | $ 47.40B | $ 7.61B | $ 22.22B |
| 2004 | $ 52.51B | $ 11.33B | $ 19.89B |
| 2003 | $ 45.18B | $ 3.91B | $ 11.95B |
| 2002 | $ 32.37B | $ 9.12B | $ 12.55B |
| 2001 | $ 32.25B | $ 7.78B | $ 8.61B |
| 2000 | $ 29.57B | $ 3.72B | $ 6.86B |
| 1999 | $ 16.20B | $ 3.17B | $ 6.38B |
| 1998 | $ 13.54B | $ 3.35B | $ 1.55B |
| 1997 | $ 12.50B | $ 2.21B | $ 877M |
| 1996 | $ 11.30B | $ 1.92B | $ 1.15B |
| 1995 | $ 10.02B | $ 1.57B | $ 403M |
| 1994 | $ 8.28B | $ 1.29B | $ 1.45B |
| 1993 | $ 7.47B | $ 657M | $ 729M |
| 1992 | $ 7.23B | $ 810M | $ 1.25B |
| 1991 | $ 6.95B | $ 722M | $ 1.31B |
| 1990 | $ 6.40B | $ 801M | $ 870M |
| 1989 | $ 5.67B | $ 681M | $ 825M |
| 1988 | $ 5.38B | $ 791M | $ 807M |
| 1987 | $ 4.91B | $ 690M | $ 1.03B |
| 1986 | $ 4.47B | $ 660M | $ 398M |
| 1985 | $ 4.02B | $ 579M | $ 412M |
Pfizer Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 41.65B to $ 62.57B and net income declined from $ 9.15B to $ 7.77B. Revenue increased in 3 of those 5 years; net income in 2.
Across Pfizer Inc's full reported history, from 1985 to 2025, revenue grew from $ 4.02B to $ 62.57B and net income grew from $ 579M to $ 7.77B. Revenue increased in 73% of the years measured; net income in 61%.
Pfizer Inc currently holds a 20-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.
Membership
Continue PFE’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
